CAR T-Cell Therapy Package

Medical Visa
Assistance

Tele-Video
Consultation

Language Interpretation
Services

Second Medical
Opinion

Post-Treatment
Care Coordination

Coordinating care at accredited hospitals, including

Apollo HospitalsFortis HealthcareManipal HospitalsSarvodaya Hospital

Not sure where to start? Get a free medical opinion

Not sure what your treatment will cost? Free, instant, itemised estimate -- treatment, visa, flights, hotel & food

What will your treatment cost?

Chat Assistance

Surgery Name	Cost	Room	Hospitalization
CAR T-Cell Therapy Package	USD 1500 - USD 2000	OPD	OPD
Bridge Treatment (Depending upon condition)	USD 15000 – USD 38000 (depending upon reports)	Depending upon condition(OPD/Admission)	Depending upon condition(OPD/Admission)
CAR T Cell Manufacturing Cost	USD 60000 (to be paid directly to manufacturer)	Private	Can take up to 8 weeks
CAR T infusion and post management cost	USD 38000	Private	Depending upon condition

✓ Inclusion

✔Consultation with a haemato-oncologist / bone marrow transplant specialist
✔Detailed review of previous biopsy, flow cytometry, PET-CT and treatment history
✔Basic evaluation blood tests as per hospital package (blood counts, organ function)
✔Counselling on suitability, choice of CAR-T product (Indian or imported) and expected results
✔Written treatment plan with timeline (bridging, collection, manufacturing, infusion, follow-up)
✔Written cost estimate for each stage of treatment
✔Guidance on approvals and documents needed
✔Tele-consultation before travel to India
✔Free: airport pick-up & drop, visa invitation letter, interpreter & coordinator (Satyug Healthcare)

✗ Exclusion

✖Air tickets, visa fees and travel insurance
✖Hotel or apartment stay for the 2–3 month treatment period
✖PET-CT, bone marrow biopsy, MRI and other advanced investigations
✖Bridging chemotherapy or radiotherapy (about USD 15,000–38,000, depending upon reports)
✖T-cell collection (apheresis) charges
✖CAR T-cell manufacturing / product cost (about USD 60,000 for the product listed, paid directly to the manufacturer)
✖CAR-T infusion, hospital stay, ICU care and post-infusion management (about USD 38,000)
✖Drugs for side effects (tocilizumab, steroids, immunoglobulin, antibiotics)
✖Blood and platelet transfusions
✖Long-term follow-up tests

Know More About Procedure & Surgery

🇮🇳 CANCER CELL THERAPY — INDIA

CAR T-Cell Therapy in India

Personalised immune-cell therapy for blood cancers that came back or did not respond to chemotherapy – B-cell leukaemia, lymphoma and myeloma – at leading Indian haematology and bone marrow transplant centres. This USD 1,500 package covers the initial evaluation and planning.

✅ Free Medical Opinion in 48–72 h🧬 Made-in-India & Imported CAR-T Options💰 Evaluation from USD 1,500✈️ Visa & Airport Support🗣️ Interpreter Available

🧪

2–6 weeks

Cell manufacturing

🏥

OPD

Evaluation package

📈

60–90%

Response rate

📅

2–3 months

Total stay in India

📖 What is CAR T-Cell Therapy?

Our immune system has white blood cells called T-cells that attack germs and abnormal cells. Some blood cancers hide from these T-cells. In CAR T-cell therapy, the patient's own T-cells are collected from the blood, sent to a special laboratory and changed so they carry a new receptor called a chimeric antigen receptor (CAR). This receptor works like a homing device that finds a marker on cancer cells – for example CD19 on B-cell leukaemia and lymphoma, or BCMA on myeloma.

The changed cells are multiplied into millions and given back as a single drip (infusion), after a few days of mild chemotherapy that makes space for them. The CAR T-cells then grow inside the body and kill the cancer cells. It is a one-time treatment, used mainly when cancer has come back or has not responded to at least two earlier treatments. India now has its own approved CAR-T therapy (NexCAR19, approved by CDSCO in 2023), which costs much less than imported products.

🩺 Conditions Treated

🩸

B-cell acute lymphoblastic leukaemia (ALL)

Relapsed or resistant ALL in children and young adults.

🎗️

Diffuse large B-cell lymphoma

Lymphoma that came back or did not respond after 1–2 lines of treatment.

🔵

Follicular & mantle cell lymphoma

Relapsed low-grade or mantle cell lymphoma after several treatments.

🦴

Multiple myeloma

Relapsed myeloma using BCMA-targeted CAR-T cells.

🔁

Relapse after transplant

Blood cancers returning after a bone marrow transplant (selected cases).

🧪

Clinical trials

New CAR-T treatments under study in Indian centres for other cancers.

⚠️ Signs That CAR-T May Be Considered

➤Leukaemia or lymphoma that came back
➤No response to 2 or more chemotherapy lines
➤Relapse after bone marrow transplant
➤Not fit for or no donor for transplant

➤Myeloma relapsing after several drugs
➤Swollen lymph nodes returning after treatment
➤Rising abnormal cells in blood or marrow
➤Positive PET scan after chemotherapy

💡 CAR-T is not a first treatment. Most blood cancers are first treated with chemotherapy, immunotherapy and sometimes a bone marrow transplant, which cure many patients. CAR-T is considered when these fail. Patients must be fit enough, have suitable T-cells and controlled infections; very weak patients or those with uncontrolled disease in the brain may not be suitable.

🔬 Tests Before Treatment

Test	Why it is done
PET-CT scan	Shows how much lymphoma or myeloma is active and where.
Bone marrow biopsy and flow cytometry	Measures leukaemia or myeloma cells and confirms the CD19 or BCMA marker.
Complete blood count and lymphocyte count	Checks if enough T-cells can be collected.
Heart (echo, ECG) and lung tests	Ensure the body can handle side effects like cytokine release.
Liver and kidney function	Check organ fitness for chemotherapy and cell infusion.
Infection screening (HIV, hepatitis B/C, others)	Required before cell collection and treatment.
Brain MRI / lumbar puncture (selected)	Checks for cancer in the brain or spinal fluid.

🏥 The Procedure — Step by Step

Evaluation (this package)

Haematologist consultation, review of reports, key tests and counselling on suitability, cost and timeline.

Approval and planning

Product chosen (Indian or imported), approvals and financial clearance completed.

T-cell collection (apheresis)

Blood is passed through a machine for 3–5 hours to collect T-cells; the rest is returned.

Cell manufacturing

Cells are engineered and grown in the lab – about 2–3 weeks for Indian products, up to 6–8 weeks for some imported ones.

Bridging therapy

Chemotherapy or radiation keeps the cancer under control while cells are made.

Lymphodepletion

3 days of mild chemotherapy (fludarabine and cyclophosphamide) make space for the new cells.

CAR-T infusion

The cells are given as a 15–30 minute drip, like a blood transfusion.

Close monitoring

Hospital or daily monitoring for 1–2 weeks for fever (CRS) and nerve side effects.

Staying near the centre

Patients stay within easy reach of the hospital for about 4 weeks after infusion.

Response check

PET-CT or bone marrow test at about 1 month and 3 months to check the response.

⚖️ CAR-T Options & Related Treatments

Option	What is done	Best for
Indian CD19 CAR-T (e.g. NexCAR19)	CDSCO-approved CAR-T made in India	Relapsed B-cell ALL and B-cell lymphoma – lower cost
Imported CD19 CAR-T	International commercial products where available	Selected lymphoma and leukaemia cases
BCMA CAR-T	CAR-T aimed at the BCMA marker	Relapsed multiple myeloma
Clinical trial CAR-T	New products under study	Patients eligible for trials
Bone marrow transplant	Stem cells from a donor or the patient	Patients fit for transplant with a donor

📊 In pivotal trials, about 80% of children and young adults with relapsed B-cell ALL went into remission after CAR-T (ELIANA, NEJM 2018), and about 40% of patients with resistant large B-cell lymphoma remained in long-term remission (ZUMA-1); Indian NexCAR19 trial data reported responses in about 70% of patients with fewer severe side effects.

📅 Your Day-by-Day Plan in India

Day	What happens
Week 1	Arrival in India ✈️, haematology consultation, tests and counselling (this package)
Week 1–2	Approvals, T-cell collection (apheresis), start of bridging therapy if needed
Week 2–6	Cell manufacturing while bridging treatment continues (OPD or admission)
Week 6–7	Lymphodepletion chemotherapy and CAR-T infusion – hospital monitoring
Week 7–10	Stay near the hospital, regular check-ups and blood tests
Week 10–12	Response assessment (PET-CT / marrow), follow-up plan – Fly home ✈️

🌱 Recovery After Treatment

🌡️

Week 1–2

Fever and low blood pressure (CRS) may occur; treated quickly in hospital.

🧠

Week 1–4

Watch for confusion, speech or handwriting changes (ICANS); report at once.

🏨

Week 1–4

Stay within 1–2 hours of the hospital with a caregiver at all times.

🚗

Week 1–8

No driving or operating machines for 8 weeks after infusion.

🛡️

Month 1–6

Low blood counts and infections possible; some need immunoglobulin infusions.

🩺

Long term

Regular blood tests and scans; lifelong yearly check for very late effects.

🏆 Success Rate

Outcome	Result
Remission in relapsed B-cell ALL	About 80–90%
Overall response in large B-cell lymphoma	About 50–80%
Long-term remission in large B-cell lymphoma	About 30–40%
Response in relapsed myeloma (BCMA CAR-T)	About 70–95%
Severe CRS (grade 3+)	About 5–20%, product dependent

Results depend on the type of cancer, how much disease is present at infusion, the CAR-T product, how many earlier treatments were given and the patient's fitness. Lower disease burden before infusion gives better results.

🩹 Risks & Possible Complications

CAR-T therapy can have serious side effects, so it is given only in experienced centres with ICU backup.

•Cytokine release syndrome (fever, low blood pressure) – about 50–90%, severe in about 5–20%
•Nerve side effects (ICANS: confusion, speech trouble, seizures) – about 20–40%, severe in about 10–20%
•Low blood counts for weeks to months
•Infections due to weak immunity
•Low antibody levels needing immunoglobulin
•Tumour lysis syndrome – uncommon
•Treatment-related death – about 2–5%

💰 Cost of CAR T-Cell Therapy in India

CAR T-cell therapy in India starts with an evaluation and planning package from about USD 1,500 (OPD), which includes the specialist consultation, review of reports and counselling. The full treatment cost depends on the product: bridging treatment (about USD 15,000–38,000 depending on reports), CAR-T cell manufacturing (about USD 60,000 paid directly to the manufacturer for the product listed) and infusion with post-infusion care (about USD 38,000). Made-in-India CAR-T products can cost much less.

Option / Hospital tier	Approx. cost (USD)	Hospital stay	Notes
CAR-T evaluation & planning (this package)	1,500	OPD	Consultation, report review, counselling
Bridge treatment (depending upon condition)	15,000 – 38,000 (depending upon reports)	OPD / Admission	Keeps cancer controlled during manufacturing
CAR T-cell manufacturing cost	60,000 (paid directly to manufacturer)	Private	Can take up to 8 weeks
CAR-T infusion and post-infusion management	38,000	Private	Depending upon condition

⚠️ The cost may vary from case to case; these are approximate figures. Final cost depends on the cancer type, need for bridging therapy, the CAR-T product chosen, side effects and ICU needs. Quotes are confirmed after the specialist examines the patient in India.

CAR T-Cell Therapy cost comparison India USA UK Turkey

📋 What the Package Includes

✅ Included

✔Haematologist / BMT specialist consultation
✔Review of all previous reports
✔Counselling on suitability, timeline and cost
✔Basic evaluation tests as per package
✔Treatment plan in writing
✔Airport pick-up & drop
✔Interpreter and coordinator
✔Help with approvals and hospital paperwork

❌ Not Included

✖Flights and visa fees
✖Hotel or apartment stay (2–3 months)
✖PET-CT, bone marrow and advanced tests
✖Bridging chemotherapy or radiation
✖CAR-T cell manufacturing (product cost)
✖Infusion, hospital stay and ICU care
✖Medicines such as tocilizumab, immunoglobulin
✖Long-term follow-up tests

✈️ Your Medical Travel Process with Satyug Healthcare

Medical travel journey to India for CAR T-Cell Therapy

Step	Details
1. Send reports	Full diagnosis reports (biopsy, flow cytometry, immunohistochemistry showing CD19 or BCMA), recent PET-CT, bone marrow report, list of all treatments given with dates and responses, transplant details if any, and recent blood counts and organ function tests.
2. Free opinion & quotes	Within 48-72 hours you receive opinions and cost estimates from 3-5 leading hospitals to compare.
3. Choose hospital & doctor	We help you compare doctors, success rates, room options and total budget.
4. Medical visa	The hospital issues a Visa Invitation Letter (VIL) to the Indian Embassy. The patient and up to 2 attendants apply for an e-Medical / Medical Attendant visa.
5. Travel planning	Flight guidance, wheelchair assistance, airport pick-up, hotel or guest house near the hospital.
6. Treatment in India	Your coordinator and interpreter stay with you for admission, treatment, discharge and billing.
7. Return & follow-up	Fit-to-fly letter, medicines, and online follow-up with your doctor after you return home.

🎒 Travel Checklist

📌Valid passport (6+ months) for the patient and attendants, plus 10 passport-size photos each
📌Medical visa / e-visa and the hospital’s Visa Invitation Letter
📌All biopsy, flow cytometry, PET-CT and bone marrow reports, treatment history, scans on CD / link and prescriptions
📌Yellow fever vaccination certificate (mandatory for travellers from African countries)
📌Polio vaccination certificate where applicable
📌Declare cash above USD 5,000 at the airport; hospitals accept wire transfer and cards
📌Foreigners staying longer than permitted must register with the FRRO — our team assists

⭐ Why Choose Satyug Healthcare?

🏥

Top Accredited Hospitals

CAR-T is offered at selected centres in India, including Tata Memorial Hospital (Mumbai), AIIMS New Delhi, and leading private bone marrow transplant units such as Apollo, Fortis Memorial Gurugram, Max Saket, Medanta, BLK-Max, Artemis, Narayana Health and Kokilaben Hospital – availability changes, so we confirm the right centre for each patient.

👨‍⚕️

Senior Specialists

Our partner haemato-oncologists and bone marrow transplant physicians are trained in CAR-T delivery and in managing its side effects with dedicated ICU support.

💵

Transparent Pricing

Multiple written quotes to compare — no hidden charges, no extra fee for our service.

🤝

End-to-End Support

Visa, airport pick-up, accommodation, interpreter and 24/7 coordinator.

❓ Frequently Asked Questions

➤ What is the cost of CAR T-cell therapy in India?

The evaluation package starts from USD 1,500. The full treatment, including bridging therapy, the CAR-T product and post-infusion care, usually ranges from about USD 45,000 with a made-in-India product to about USD 140,000 with an imported product. This is far less than in the USA or Europe.

➤ What does the USD 1,500 package include?

It covers the specialist consultation, review of all your reports, key evaluation and counselling on whether CAR-T suits you, which product, the timeline and total cost. It does not include the CAR-T product itself.

➤ How long do I need to stay in India?

Usually about 2–3 months: evaluation and cell collection, 2–8 weeks of manufacturing with bridging therapy, the infusion, and about 4 weeks of close follow-up near the hospital.

➤ Is CAR-T available in India?

Yes. India approved its own CAR-T therapy (NexCAR19) in 2023 for B-cell leukaemia and lymphoma, and other products and clinical trials are available at selected centres. Some products may need special regulatory approval for each patient.

➤ How successful is CAR-T therapy?

About 80–90% of patients with relapsed B-cell ALL go into remission, and about 30–40% of patients with resistant large B-cell lymphoma stay in long-term remission. Results vary by cancer and patient.

➤ What are the main side effects?

Cytokine release syndrome (high fever, low blood pressure) and nerve side effects (confusion, speech problems). They are usually temporary and are treated with medicines like tocilizumab and steroids in hospital.

➤ Is CAR-T painful?

The infusion itself is like a blood transfusion and is not painful. Cell collection is similar to giving blood but takes a few hours.

➤ Who is suitable for CAR-T?

Patients with B-cell ALL, B-cell lymphoma or myeloma that came back or did not respond to earlier treatments, who are fit enough and have no uncontrolled infection. The specialist decides after evaluation.

➤ Can children have CAR-T?

Yes. Children and young adults with relapsed B-cell ALL are among the patients who benefit most. Paediatric haematology teams manage their care.

➤ Is CAR-T a cure?

For some patients it gives long-lasting remission that may be a cure, especially in lymphoma and ALL. Others may relapse and need further treatment such as a transplant.

➤ Why does the bridge treatment take so long?

The cancer must be kept under control while the cells are being made, which takes 2–8 weeks depending on the product. Bridging chemotherapy or radiation does this.

➤ Can a family member come with me?

Yes, and a caregiver must be with you at all times for at least 4 weeks after infusion. Up to two attendants can come on a medical attendant visa; we send the invitation letter.

➤ What follow-up is needed after going home?

Blood counts, immunoglobulin levels and scans at regular intervals, and vaccinations later. Your Indian doctors guide your local team and follow you up by video.

➤ Should I have a tele-consultation before travelling?

Yes. We strongly advise a video consultation with the CAR-T specialist before you travel, to confirm suitability, product choice, timeline and total cost.

💬 Get a Free Opinion & Cost Estimate

Send your medical reports today and receive opinions from India’s top specialists within 48-72 hours.

📞 +91-8860606766 | +91-9910655125 | ✉️ query@satyughealthcare.com

Medical disclaimer: This page is for general information and does not replace a consultation with a qualified specialist. Treatment plans and costs are confirmed only after the patient is examined. Sources: NCBI StatPearls: CAR T-Cell Therapy; Maude et al., NEJM 2018 (ELIANA); Neelapu et al., NEJM 2017 (ZUMA-1); CDSCO approval of NexCAR19 (2023); ASTCT consensus grading for CRS and ICANS (2019); National Cancer Institute: CAR T Cells; Leukemia & Lymphoma Society. Infographics: Satyug Healthcare.